SCHEMBL9979773

SCHEMBL9979773

CC(=O)OCc1ccc2oncc2c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.49
CA2 P00918 3/20 0.44
ALDH1A1 P00352 2/20 0.44
LMNA P02545 2/20 0.40
TP53 P04637 1/20 0.40
CA12 O43570 2/20 0.36
CA3 P07451 2/20 0.36
CA6 P23280 2/20 0.36
CA7 P43166 2/20 0.36
CA9 Q16790 2/20 0.36
CA14 Q9ULX7 2/20 0.36
CA5B Q9Y2D0 2/20 0.36
CA4 P22748 1/20 0.36
CYP1A2 P05177 1/20 0.35
CYP2C19 P33261 1/20 0.35
CA5A P35218 1/20 0.35
TRPM5 Q9NZQ8 1/20 0.34
S1PR4 O95977 1/20 0.34
IDH1 O75874 1/20 0.34
KDM4E B2RXH2 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9976426 0.86 LMNA (0.39) CYP3A4CA2ALDH1A1LMNATP53
SCHEMBL3290937 0.85 ALDH1A1 (0.44) CYP3A4CA2ALDH1A1LMNATP53
SCHEMBL115421 0.85 LMNA (0.40) CYP3A4CA2LMNATP53TRPM5
SCHEMBL20079989 0.80 LMNA (0.49) CA2LMNATP53TRPM5KDM4E
SCHEMBL4186791 0.77 CYP3A4 (0.59) CYP3A4CA2ALDH1A1LMNATP53
SCHEMBL13500589 0.77 NPC1 (0.49) ALDH1A1LMNATP53KDM4ESYK
SCHEMBL17955752 0.76 CYP3A4 (0.51) CYP3A4CA2ALDH1A1LMNATP53
SCHEMBL13500632 0.75 GAA (0.50) CA2ALDH1A1LMNAKDM4EHSD17B10
SCHEMBL8179979 0.74 CYP1A2 (0.44) ALDH1A1LMNATP53CYP1A2TRPM5
SCHEMBL11320167 0.74 CYP3A4 (0.56) CYP3A4CA2ALDH1A1LMNATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2751076-B1 SYNTHESIS METHOD AND INTERMEDIATES USEFUL IN THE PREPARATION OF PYRROLOBENZODIAZEPINES MEDIMMUNE LTD (GB) 2018-04-25 EP disclosed
EP-2558445-B1 INTERMEDIATES USEFUL FOR THE SYNTHESIS OF PYRROLOBENZODIAZEPINES MEDIMMUNE LTD (GB) 2017-03-22 EP disclosed
US-9102704-B2 Synthesis method and intermediates useful in the preparation of pyrrolobenzodiazepines SPIROGEN SARL (CH) 2015-08-11 US disclosed
US-20140275522-A1 SYNTHESIS METHOD AND INTERMEDIATES USEFUL IN THE PREPARATION OF PYRROLOBENZODIAZEPINES SPIROGEN SÁRL (CH) 2014-09-18 US disclosed
US-8829184-B2 Intermediates useful for the synthesis of pyrrolobenzodiazepines SPIROGEN SARL (CH) 2014-09-09 US disclosed
US-8779191-B2 Methods and compositions for preparing lisdexamfetamine and salts thereof CAMBREX CHARLES CITY, INC. (US) 2014-07-15 US disclosed
WO-2013053872-A1 SYNTHESIS METHOD AND INTERMEDIATES USEFUL IN THE PREPARATION OF PYRROLOBENZODIAZEPINES SPIROGEN SÀRL (CH) 2013-04-18 WO disclosed
US-20130035484-A1 INTERMEDIATES USEFUL FOR THE SYNTHESIS OF PYRROLOBENZODIAZEPINES SPIROGEN DEVELOPMENTS SÀRL (CH) 2013-02-07 US disclosed
US-20120190880-A1 METHODS AND COMPOSITIONS FOR PREPARATION OF AMPHETAMINE CONJUGATES AND SALTS THEREOF BLUE OWL CAPITAL CORPORATION, AS NEW AGENT 2012-07-26 US disclosed
US-20120157706-A1 Methods and Compositions for Preparing Lisdexamfetamine and Salts Thereof AVISTA PHARMA SOLUTIONS, INC. 2012-06-21 US disclosed
US-20100056497-A1 AMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD (JP) 2010-03-04 US disclosed
US-20100056497-A1 AMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD (JP) 2010-03-04 US disclosed
EP-2119702-A1 AMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2009-11-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190880-A1 METHODS AND COMPOSITIONS FOR PREPARATION OF AMPHETAMINE CONJUGATES AND SALTS THEREOF PNMT, COMT, DDT CYP3A4 383/4885CA2 3935/4885ALDH1A1 616/4885
US-20120157706-A1 Methods and Compositions for Preparing Lisdexamfetamine and Salts Thereof SLC6A3, COMT, LPXN CYP3A4 616/4885CA2 4694/4885ALDH1A1 1883/4885
US-20140275522-A1 SYNTHESIS METHOD AND INTERMEDIATES USEFUL IN THE PREPARATION OF PYRROLOBENZODIAZEPINES ORC3, OXER1, SCO2 CYP3A4 116/4885CA2 1869/4885ALDH1A1 3535/4885
US-20100056497-A1 AMIDE DERIVATIVE REN, AGTR1, AGTR2 CYP3A4 537/4885CA2 168/4885ALDH1A1 348/4885
US-20130035484-A1 INTERMEDIATES USEFUL FOR THE SYNTHESIS OF PYRROLOBENZODIAZEPINES CYP11B2, CYP1B1, CYP11B1 CYP3A4 39/4885CA2 4220/4885ALDH1A1 963/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.